DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • India
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
NATCOPHARM logo

NATCO Pharma Limited Stock Price

NSEI:NATCOPHARM Community·₹148.0b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 119 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

NATCOPHARM Share Price Performance

₹826.30
-17.95 (-2.13%)
​
₹1,021.22
Fair Value
₹826.30
-17.95 (-2.13%)
19.1% undervalued intrinsic discount
₹1,021.22
Fair Value
Price ₹826.30
AnalystConsensusTarget ₹1,021.22
AnalystHighTarget ₹1,220.00
AnalystLowTarget ₹712.00
Wed, 1 Jul 26
Fair Value₹1,021.22
Share Pricen/a

NATCOPHARM Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value ₹1.02k 19.1% undervalued intrinsic discount

High-value R&D And South Africa Entry Will Shape Uncertain Outcomes

2users have liked this narrative
0users have commented on this narrative
52users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value ₹1.22k 32.3% undervalued intrinsic discount

Global Healthcare Trends Will Expand Affordable Generics Amid Risks

1users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value ₹712 16.1% overvalued intrinsic discount

Falling Revenues And Risky Diversifications Will Weaken Future Outlook

0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
NATCOPHARM logo
NATCO Pharma
19.1% undervalued intrinsic discount

High-value R&D And South Africa Entry Will Shape Uncertain Outcomes

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 1 Jul
Read Narrative
NATCOPHARM logo
NATCO Pharma
32.3% undervalued intrinsic discount

Global Healthcare Trends Will Expand Affordable Generics Amid Risks

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 17 Jun
Read Narrative
NATCOPHARM logo
NATCO Pharma
16.1% overvalued intrinsic discount

Falling Revenues And Risky Diversifications Will Weaken Future Outlook

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Published 18 Jul 2025
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
NATCOPHARM logo

NATCOPHARM: Future Oncology Upside And Margin Gains Will Meet Softer Expectations

Fair Value: ₹1.02k 19.1% undervalued intrinsic discount
52 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
NATCOPHARM logo

NATCOPHARM: Oncology And Diabetes Pipeline Will Drive Share Price Upside

Fair Value: ₹1.22k 32.3% undervalued intrinsic discount
12 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
NATCOPHARM logo

Falling Revenues And Risky Diversifications Will Weaken Future Outlook

Fair Value: ₹712 16.1% overvalued intrinsic discount
5 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Excellent balance sheet average dividend payer.

2 Risks
2 Rewards
View Full Analysis

NATCO Pharma Limited Key Details

₹34.8b

Revenue

₹6.1b

Cost of Revenue

₹28.8b

Gross Profit

₹17.4b

Other Expenses

₹11.4b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
63.89
82.64%
32.84%
7.7%
View Full Analysis

About NATCOPHARM

Founded
1981
Employees
4433
CEO
Rajeev Nannapaneni
WebsiteView website
www.natcopharma.co.in

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Recent NATCOPHARM News & Updates

Analysis Article • Aug 18

NATCO Pharma Limited Recorded A 5.3% Miss On Revenue: Analysts Are Revisiting Their Models

NATCO Pharma Limited ( NSE:NATCOPHARM ) shareholders are probably feeling a little disappointed, since its shares fell...

Recent updates

No updates

NATCO Pharma Limited Competitors

SUNPHARMA logo

Sun Pharmaceutical Industries

Symbol: NSEI:SUNPHARMA
Market cap: ₹4.5t
DIVISLAB logo

Divi's Laboratories

Symbol: NSEI:DIVISLAB
Market cap: ₹2.5t
500420 logo

Torrent Pharmaceuticals

Symbol: BSE:500420
Market cap: ₹1.9t
ZYDUSLIFE logo

Zydus Lifesciences

Symbol: NSEI:ZYDUSLIFE
Market cap: ₹1.1t
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide